Continuous Sweat Analysis Patch SweatSense Approved by FDA: Real-Time Monitoring of Inflammation Markers and Drug Levels Through Perspiration

Wearable medical device company Eccrine Systems announced on May 5 that its sweat analysis patch SweatSense has received FDA De Novo classification clearance. This coin-sized flexible patch, applied to the inner forearm, uses a microfluidic chip to continuously collect and analyze multiple biomarkers in sweat, including C-reactive protein (inflammation marker), cortisol (stress hormone), uric acid (gout indicator), and specific drug metabolite concentrations.

SweatSense's breakthrough resolves a longstanding challenge in sweat analysis — biomarker concentrations in sweat are 2 to 3 orders of magnitude lower than in blood, far below traditional sensor sensitivity. Eccrine Systems uses a molecularly imprinted polymer-based nano-sensor array achieving picomolar detection limits, comparable to laboratory blood test sensitivity.

Clinical trial data shows SweatSense's C-reactive protein measurements correlate with venous blood test results at a coefficient of 0.94, and cortisol at 0.91. This means in most clinical scenarios, SweatSense can replace frequent blood draws. CEO Dr. Gavi Begtrup said initial applications include inflammation monitoring for rheumatoid arthritis patients and immunosuppressive drug concentration adjustment for organ transplant recipients — both populations requiring frequent blood tests to track treatment response.